Overactive Bladder Therapeutics Market Size to Grow by $ 311.17 Mn through 2020-2024 | Forecast and Trend Analysis
Technavio has been monitoring the overactive bladder therapeutics market and it is expected to grow by $ 311.17 million, accelerating at a CAGR of almost 2% during the forecast period. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking View Free Sample Report
Overactive Bladder Therapeutics Market: Emerging Trends to Impact Market Growth
Advent of combination therapy to emerge as a key trend in the industrial overactive bladder therapeutics market. This report provides a detailed analysis of all the trends that are likely to influence the growth of individual segments within the market as well as the overall market in focus. This analysis will enable clients to assess their play in the market and plan for growth opportunities.
Overactive Bladder Therapeutics Market: Vendor Analysis
The market is fragmented due to the presence of several players. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. AbbVie Inc., Astellas Pharma Inc., Endo International Plc, Johnson & Johnson, Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.
Technavio custom reports provide market insights at the global and regional level along with a pipeline analysis of new product launches. It also provides a peek into the latest R&D along with an impact analysis of government regulations.
For more insights into this market:Download a Free Sample Report
Technavio has been monitoring the global overactive bladder (OAB) therapeutics market and it is expected to grow by USD 311.17 million accelerating at a CAGR of almost 2% during the forecast period. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking. Download latest version with COVID-19 analysis Free Sample Report
This report provides a detailed analysis of the overactive bladder therapeutics market by Product (Anticholinergics, Beta-3 adrenergic agonists, and Other OAB therapeutics) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024. The report also provides a detailed analysis of around 25 vendors operating in the overactive bladder therapeutics market.
Overactive Bladder Therapeutics Market: Segmentation by Product
During 2019, the anticholinergics segment accounted for the major share of the Overactive Bladder Therapeutics Market. The administration of anticholinergics has remained the mainstay treatment. However, increasing R&D in drug development has recently given rise to beta-3 adrenergic agonists. Despite the therapeutic efficacy of these drugs, which are administered as monotherapy, they are associated with adverse effects. Therefore, there is a significant unmet need for effective therapeutics for the treatment of OAB. As a result, vendors are increasingly spending on R&D to launch improved drugs. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. It also involves a shorter duration of treatment, improving patient compliance. As a result, the demand for combination therapy drugs is increasing. The advent of combination therapy is expected to significantly contribute to overactive bladder therapeutics market growth during 2020-2024.
Overactive Bladder Therapeutics Market: Vendor Analysis
The market is fragmented. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. AbbVie Inc., Astellas Pharma Inc. and Endo International Plc are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.
Technavio offers custom research reports with detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will help clients keep up with new product launches in direct & indirect COVID-19 related markets. It will also provide insights on upcoming developments along with pipeline analysis of vendor operations and the impact of government regulations.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19 Download a Free Sample Report
